Molecular imaging of tumor angiogenesis

Annals of the New York Academy of Sciences

Volumn 1014, Issue , 2004, Pages 67-75

  Schirner, Michael ^a   Menrad, Andreas ^a   Stephens, Andrew ^a   Frenzel, Thomas ^a   Hauff, Peter ^a   Licha, Kai ^a  

^a BAYER PHARMA AG   (Germany)

Author keywords

Angiogenesis; Antibodies; Antibody fragments; Imaging; Magnetic resonance imaging (MRI); Molecular imaging; Nuclear medicine; Optical imaging; Tumor angiogenesis; Ultrasound

Indexed keywords

ANGIOGENIC FACTOR; CONTRAST MEDIUM; FLUORESCENT DYE; FLUORODEOXYGLUCOSE; RADIOISOTOPE;

ANGIOGENESIS; BIOCOMPATIBILITY; BLOOD VESSEL PERMEABILITY; BLOOD VOLUME; CANCER DIAGNOSIS; COMPUTER ASSISTED TOMOGRAPHY; CONTRAST ENHANCEMENT; ECHOGRAPHY; HUMAN; IMAGING; MOLECULAR BIOLOGY; NEOVASCULARIZATION (PATHOLOGY); NUCLEAR MAGNETIC RESONANCE IMAGING; PATHOPHYSIOLOGY; POSITRON EMISSION TOMOGRAPHY; PROTEIN TARGETING; RADIODIAGNOSIS; REVIEW; TECHNIQUE; TUMOR BLOOD FLOW; TUMOR VASCULARIZATION;

EID: 2342663709     PISSN: 00778923     EISSN: None     Source Type: Book Series    
DOI: 10.1196/annals.1294.007     Document Type: Review

References (45)

1. FOLKMAN, J. 1971. Tumor angiogenesis: therapeutic implication. N. Engl. J. Med. 285: 1182-1186.
2. DENEKAMP, J. 1984. Vascular endothelium as the vulnerable element in tumors. Acta Radiol. Oncol. 23: 217-225.
3. TARLI, L., E. BALZA, F. VITI, et al. 1999. A high-affinity human antibody that targets tumoral blood vessels. Blood 94: 192-198.
4. SANTIMARIA, M., G. MOSCATELLI, G.L. VIALE, et al. 2003. Immunoscintigraphic detection of the ED-B domain of fibronectin, a marker of angiogenesis, in patients with cancer. Clin. Cancer Res. 9: 571-579.
5. HOLMES, E.H. 2001. PSMA specific antibodies and their diagnostic and therapeutic use. Expert Opin. Invest. Drugs 10: 511-519.
6. RAN, S., A. DOWNES & P.E. THORFE. 2002. Increased exposure of anionic phospholipids on surface of tumor blood vessels. Cancer Res. 62: 6132-6140.
7. SCHMITTGEN, T.D., B.A. ZAKRAJSEK, R.E. HILL, et al. 2003. Expression pattern of mouse homologue of prostate-specific membrane antigen (FOLH1) in the transgenic adenocarcinoma of the mouse prostate model. Prostate 55: 308-316.
8. BREMER, C., C.H. TUNG & R. WEISSLEDER. 2001. In vivo molecular target assessment of matrix metalloproteinase inhibition. Nat. Med. 7: 743-748.
9. ST. CROIX, B., C. RAGO, V. VELCULESCU, et al. 2000. Genes expressed in human tumor endothelium. Science 289: 1197-1202.
10. GEORGE, A.J.T, L. LEE & C. PITZALIS. 2003. Isolating ligands specific for human vasculature using in vivo phage selection. Trends Biotechnol. 21: 199-203.
11. HALIN, C., L. ZARDI & D. NERI. 2001. Antibody-based targeting of angiogenesis. News Physiol. Sci. 16: 191-194.
12. ZALUTSKY, M.R., R.P. MOSELY, H.B. COAKHAM, et al. 1989. Pharmacokinetics and tumor localization of I-131-labeled anti-tenascin monoclonal antibody 81C6 in patients with gliomas and other intracranial malignancies. Cancer Res. 49: 2807-2813.
13. 3 integrin binding peptides. Cancer Res. 62: 6146-6151.
14. AKABANI, G., R.E. MCLENDON, D.D. BIGNER & M.R. ZALUTSKY. 2002. Vascular targeted endoradiotherapy of tumors using alpha-particle-emitting compounds: theoretical analysis. Int. J. Radiation Oncol. Biol. Physiol. 54: 1259-1275.
15. GARCIA-BARROS, M. et al. 2003. Tumor response to radiotherapy regulated by endothelial cell papooses. Science 300: 1155-1159.
16. BRASCH, R. & K.C.P. LI. 2000. In vivo monitoring of tumor angiogenesis with MR imaging. Acad. Radiol. 7: 812-823.
17. NEEMAN, M. 2002. Functional and molecular MR imaging of angiogenesis: seeing the target, seeing it work. J. Cell. Biochem. 39: 11-17.
18. BOGDANOV, A., M. LEWIN & R. WEISSLEDER. 1999. Approaches and agents for imaging the vascular system. Adv. Drug Deliv. Res. 37: 279-293.
19. MISSELWITZ, B., H. SCHMITT-WILLICH, W. EBERT, et al. 2001. Pharmacokinetic of Gadomer-17, a new dendrimeric magnetic resonance contrast agent. Magma 12: 128-134.
20. TURETSCHEK, K, A. PREDA, E. FLOYD, et al. 2003. MRI monitoring of tumor response following angiogenesis inhibition in an experimental human breast cancer model. Eur. J. Nucl. Med. 30: 448-455.
21. TOMBACH, B., P. REIMER, M. MAHLER, et al. 2002. First-pass and equilibrium phase MRA following intravenous bolus injection of SHU 555 C: Phase I clinical trial in elderly volunteers with risk factors for arterial vascular disease. Acad. Radiol. 9 (Suppl. 2): 425-427.
22. VERHOYE, M, B.P. VAN DER SANDEN, P.F. RIJKEN, et al. 2002. Assessment of the neovascular permeability in glioma xenografts by dynamic T(1) MRI with Gadomer-17. Magn. Reson. Med. 47: 305-313.
23. SIPKINS, D.A, D.A. CHERESH, M.R. KAZEMI, et al. 1998. Detection of tumor angiogenesis in vivo by alphavbeta3-targeted magnetic resonance imaging. Nature Med. 4: 623-626.
24. SIPKINS, D.A., K. GIJBELS, F.D. TROPPER, et al. 2000. ICAM-1 expression in autoimmune encephalitis visualized using magnetic resonance imaging. J. Neuroimmunol. 104: 1-9.
25. NUNN, A.D, K.E. LINDER & M.F. TWEEDLE. 1997. Can receptors be imaged with MRI agents? Q. J. Nucl. Med. 41: 155-162.
26. CARRASQUILLO, J.A. 1989. Radioimmunoscintigraphy with polyclonal or monoclonal antibodies. In Antibodies in Radiodiagnosis and Therapy. M.R. Zalutski, Ed. :169-198. CCR Press. Boca Raton, FL.
27. LOUIE, A.Y, M.M. HUEBER, E.T. AHRENS, et al. 2000. In vivo visualization of gene expression using magnetic resonance imaging. Nature Biotechnol. 18: 321-325.
28. KONDA, S.D, M AREF, S. WANG, et al. 2001 Specific targeting of folate-dendrimer MRI contrast agents to the high affinity folate receptor expressed in ovarian tumor xenografts. Magma 12: 104-113.
29. WILD, J.J. 1950. The use of ultrasonic pulses for the measurement of biological tissues and the detection of tissue density changes. Surgery 27: 183-188.
30. ALBRECHT, T. & R.F. MATTREY. 1999 Tumor imaging with ultrasound contrast. In Trends in Contrast Media. H.S. Thomsen, R.N. Muller & R.F. Mattrey, Eds. :367-382. Springer-Verlag. Berlin, Heidelberg.
31. v-integrins. Circulation 107: 455-460.
32. LINDNER, J.R., J. SONG, J. CHRISTIANSEN, et al. 2001. Ultrasound assessment of inflammation and renal tissue injury with microbubbles targeted to P-selectin. Circulation 104: 2107-2112.
33. MÄURER, M., R. LINKER, H.P. HAUFF, et al. 2002. Imaging of ICAM-1 in experimental autoimmune encephalomyelitis (EAE) with a specific ultrasound contrast agent. J. Neurol. 249 (suppl. 1): I/57.
34. LICHA, K. 2002. Contrast agents for optical imaging. In Topics in Current Chemistry: Contrast Agents II. W. Krause, Ed. 222: 1-31. Springer. Heidelberg.
35. WEISSLEDER, R. & V. NTZIACHRISTOS. 2003. Shedding light into live molecular targets. Nature Med. 9: 123-128.
36. NTZIACHRISTOS, V., C. BREMER & R. WEISSLEDER. 2002. Fluorescence imaging with near-infrared light: new technological advances that enable in vivo molecular imaging. Eur. Radiol. 13: 195-208.
37. DAEHNE, S., U. RESCH-GENGER & O.S. WOLFBEIS (Eds). 1998. Near-infrared dyes for high technology applications, NATO ASI Series. Kluwer Academic Publishers. London.
38. BECKER, A., C. HESSENIUS, K. LICHA, et al. 2001. Receptor-targeted optical imaging of tumors with near-infrared fluorescent ligands. Nature Biotechnol. 19: 327-331.
39. BUGAJ, J.E., S. ACHILEFU, R.B. DORSHOW & R. RAJAGOPALAN. 2001. Novel fluorescent contrast agents for optical imaging of in vivo tumors based on a receptor-targeted dye-peptide conjugate platform. J. Biomed. Opt. 6: 122-133.
40. BHARGAVA, S., K. LICHA, T. KNAUTE, et al. 2002. A complete substitutional analysis of VIP for better tumor imaging properties. J. Mol. Recogn. 15: 145-153.
41. NERI D., B. CARNEMOLLA, A. NISSIM, et al. 1997. Targeting by affinity-matured recombinant antibody fragments of an angiogenesis associated fibronectin isoform. Nature Biotechnol. 15: 1271-1275.
42. BIRCHLER, M., F. VITI, L. ZARDI, et al. 1999. Selective targeting and photocoagulation of ocular angiogenesis mediated by a phage-derived human antibody fragment. Nature Biotechnol. 17: 984-988.
43. WEISSLEDER, R., C.H. TUNG, U. MAHMOOD & A. BOGNANOV. 1999. In vivo imaging of tumors with protease-activated near-infrared fluorescent probes. Nature Biotechnol. 17: 375-378.
44. MAHMOOD, U. & R. WEISSLEDER. 2003. Near-infrared optical imaging of proteases in cancer. Mol. Cancer Ther. 2: 489-496.
45. JAFFER, F.A., C.H. TUNG, R.E. GERSZTEN & R. WEISSLEDER. 2002. In vivo imaging of thrombin activity in experimental thrombi with thrombin-sensitive near-infrared molecular probe. Arterioscler. Thromb. Vasc. Biol. 22: 1929-1935.